• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Based on the provided financial report articles, the title of the article is: "Form 10-Q: [Company Name] Reports Financial Results for the Quarter Ended June 30, 2026" Note: [Company Name] is the actual company name, which is not provided in the text.

    Press release·08/10/2026 12:20:33
    Listen to the news
    Based on the provided financial report articles, the title of the article is: "Form 10-Q: [Company Name] Reports Financial Results for the Quarter Ended June 30, 2026" Note: [Company Name] is the actual company name, which is not provided in the text.

    Based on the provided financial report articles, the title of the article is: "Form 10-Q: [Company Name] Reports Financial Results for the Quarter Ended June 30, 2026" Note: [Company Name] is the actual company name, which is not provided in the text.

    The company reported a net income of $935,461 for the second quarter of 2026, with a gross profit of $1,762,232 and operating expenses of $387,000. The company’s total assets increased to $2,170,000, with cash and cash equivalents of $1,344,000 and accounts receivable of $250,000. The company’s common stock outstanding increased to 1,346,000 shares, with a book value per share of $0.3333. The company’s additional paid-in capital increased to $1,022,000, and its accumulated other comprehensive income decreased to $442,700. The company’s retained earnings increased to $1,992,000. The company’s financial position and results of operations are presented in accordance with US GAAP.

    Business Overview

    Tonix Pharmaceuticals is a fully-integrated biopharmaceutical company commercializing and developing innovative therapies for central nervous system (CNS) disorders, infectious diseases, immunology, and rare diseases. The company’s portfolio consists of both commercial and development-stage programs.

    Tonix markets TONMYA® (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults in the U.S., as well as Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray) for the treatment of acute migraine in adults in the U.S. TONMYA is Tonix’s first internally developed product to become FDA approved and is the first new medicine for fibromyalgia in more than 15 years.

    Tonix is advancing a diversified development pipeline generated through internal discovery, in-licensing, acquisitions, and collaborations. The pipeline addresses conditions spanning CNS, infectious disease, immunology, and rare disease, with multiple programs in clinical and preclinical development. Key pipeline programs include:

    • TNX-102 SL (cyclobenzaprine HCl sublingual tablets) in Phase 2 trials for major depressive disorder (MDD) and acute stress disorder (ASD)/acute stress reaction (ASR)
    • TNX-4800 (anti-Borrelia OspA human monoclonal antibody) in development for the prevention of Lyme disease
    • TNX-1500 (Fc-modified humanized monoclonal antibody targeting CD40-ligand) in development for kidney transplant rejection and autoimmune diseases
    • TNX-1300 (double-mutant cocaine esterase) in Phase 2 for the treatment of cocaine intoxication
    • TNX-2900 (intranasal oxytocin potentiated with magnesium) in development for Prader-Willi syndrome

    Tonix also has a pre-clinical infectious disease portfolio including TNX-801 (horsepox, live virus vaccine) for mpox and smallpox, and TNX-4200, a small molecule broad-spectrum antiviral agent.

    The company is led by an experienced management team and is well-capitalized, with cash resources expected to fund operations into early 2027. However, Tonix faces significant challenges and uncertainties, and may need to obtain additional financing to continue its operations and development activities.